Science & Enterprise subscription

Follow us on Twitter

  • Medical and robotics labs at two universities in Pittsburgh are developing a portable, autonomous trauma care devic… https://t.co/G8HKYrLfgi
    about 4 hours ago
  • New post on Science and Enterprise: A.I., Robotics Studied for Military Trauma System https://t.co/jkPG42ohGN #Science #Business
    about 4 hours ago
  • A biotechnology company developing immunotherapies for viral diseases is joining the ElevateBio consortium providin… https://t.co/OBytlZkrC9
    about 1 day ago
  • New post on Science and Enterprise: Viral Disease Biotech Joins ElevateBio, Gains $120M https://t.co/0NQZ9QbPhf #Science #Business
    about 1 day ago
  • Four pharmaceutical companies are signing on to an initiative that promises to make clinical trials friendlier to p… https://t.co/VNbOdOc8i5
    about 2 days ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Ostrich Antibodies to Fight Resistant Infections

A biotechnology company developing antibodies grown in ostrich eggs is partnering with a Boston hospital to test a new treatment for Clostridium difficile, or C. difficile, a stubborn infection, increasingly resistant to antibiotics, and often contracted in hospitals. . . . → Read More: Ostrich Antibodies to Fight Resistant Infections

Takeda Awarded $19.8 Million for Zika Vaccine

Takeda Pharmaceutical Company is receiving $19.8 million from a U.S. public health agency for initial steps to develop a vaccine to prevent Zika infections. . . . → Read More: Takeda Awarded $19.8 Million for Zika Vaccine

Spacecraft Returns with Space Station Research Samples

A SpaceX Dragon spacecraft returned today with samples from several biomedical research studies conducted by astronauts on the International Space Station. . . . → Read More: Spacecraft Returns with Space Station Research Samples

Hemophilia Therapy Candidate Given Breakthrough Status

(Public Domain Pictures/Pixabay)

4 September 2015. A synthetic antibody designed to prevent bleeding episodes among people with the most common type of hemophilia received a breakthrough therapy designation from the U.S. Food and Drug Administration. The pharmaceutical company Roche says FDA assigned the designation its biologic therapy code-named ACE910, now being tested in . . . → Read More: Hemophilia Therapy Candidate Given Breakthrough Status

Spin-Off Biotech Formed for Autoimmune Disorders

(Centers for Disease Control and Prevention)

2 June 2015. Drug maker Astellas Pharma Inc. in Tokyo and Anokion SA, a biotechnology company in Lausanne, Switzerland, are forming Kanyos Bio Inc., a spin-off enterprise to develop therapy candidates for autoimmune diseases. The deal could bring Kanyos Bio, based in Cambridge, Massachusetts, as much as . . . → Read More: Spin-Off Biotech Formed for Autoimmune Disorders

Astellas Getting First Access to Leukemia Antibody

Acute myeloid leukemia cells (Cancer Genome Atlas)

3 April 2015. MD Anderson Cancer Center in Houston is granting Astellas Pharma Inc. in Tokyo an option to license MD Anderson’s discovery of a synthetic antibody showing promise as a treatment for acute myeloid leukemia. For the licensing option, MD Anderson could earn up to . . . → Read More: Astellas Getting First Access to Leukemia Antibody

XPrize Awards $5.25M for Lunar Technologies

(NASA.gov)

26 January 2015. A competition to develop new technologies for landing and robotic exploration of the moon awarded $5.25 million in 9 prizes to 5 private companies, as part of the Google Lunar XPrize challenge. The companies — from the U.S., Germany, Japan, and India — received the prizes for their design . . . → Read More: XPrize Awards $5.25M for Lunar Technologies

Takada Pharma, GE Healthcare to Partner on Liver Disease

Image scan with MR Touch showing liver stiffness areas (GE Healthcare)

11 November 2014. Takada Pharmaceutical Company and GE Healthcare are collaborating on research into scarring of liver tissue that happens when damage occurs, often from fat building up in the liver, an increasingly common condition. Financial terms of the partnership, announced today . . . → Read More: Takada Pharma, GE Healthcare to Partner on Liver Disease

Simple 3-D Graphene Construction Process Devised

Electron microscope image of porous graphene-based structure created by diffusion driven layer-by-layer assembly (Kyoto University)

17 October 2014. Materials scientists at Kyoto University in Japan developed a new process that simplifies the building of three-dimension structures with graphene, a light, strong, conductive material with many industrial and commercial applications. Franklin Kim and Jianli . . . → Read More: Simple 3-D Graphene Construction Process Devised

Astellas, Harvard Partner on Retinitis Pigmentosa Targets

Constance Cepko (Harvard Medical School)

14 October 2014. Astellas Pharma Inc. in Tokyo is collaborating with a genetics and ophthalmology lab at Harvard University to discover more about the onset of the eye disease retinitis pigmentosa and identify therapy targets. Financial details of the three-year deal with Harvard were not disclosed.

Retinitis pigmentosa . . . → Read More: Astellas, Harvard Partner on Retinitis Pigmentosa Targets